A 0 1 0 1 O
review 2 8 2 8 O
of 9 11 9 11 O
a 12 13 12 13 O
previous 14 22 14 22 B-treatment
MRI 23 26 23 26 I-treatment
examination 27 38 27 38 I-treatment
may 39 42 39 42 O
help 43 47 43 47 O
confirm 48 55 48 55 O
the 56 59 56 59 O
entry 60 65 60 65 O
criteria 66 74 66 74 O
on 75 77 75 77 O
subjects 78 86 78 86 O
selected 87 95 87 95 O
to 96 98 96 98 O
come 99 103 99 103 O
to 104 106 104 106 O
Stanford 107 115 107 115 O
for 116 119 116 119 O
the 120 123 120 123 O
MRI 124 127 124 127 O
screening 128 137 128 137 O

Alpha 0 5 138 143 B-treatment
- 5 6 143 144 I-treatment
blockers 6 14 144 152 I-treatment

Also 0 4 153 157 O
excluded 5 13 158 166 O
are 14 17 167 170 O
concomitant 18 29 171 182 O
use 30 33 183 186 O
of 34 36 187 189 O
organic 37 44 190 197 B-treatment
nitrates 45 53 198 206 I-treatment
, 53 54 206 207 O
alpha 55 60 208 213 B-treatment
- 60 61 213 214 I-treatment
blockers 61 69 214 222 I-treatment
, 69 70 222 223 O
amlodipine 71 81 224 234 B-treatment
, 81 82 234 235 O
or 83 85 236 238 O
cimetidine 86 96 239 249 B-treatment

Amlodipine 0 10 250 260 B-treatment

Assent 0 6 261 267 O
obtained 7 15 268 276 O
for 16 19 277 280 O
subjects 20 28 281 289 O
7 29 30 290 291 B-lower_bound
- 31 32 292 293 O
10 33 35 294 296 B-upper_bound
years 36 41 297 302 I-upper_bound
old 42 45 303 306 O

Be 0 2 307 309 O
at 3 5 310 312 O
the 6 9 313 316 O
minimum 10 17 317 324 O
weight 18 24 325 331 B-clinical_variable
of 25 27 332 334 O
8 28 29 335 336 B-lower_bound
kg 30 32 337 339 I-lower_bound
at 33 35 340 342 O
the 36 39 343 346 O
time 40 44 347 351 O
of 45 47 352 354 O
enrollment 48 58 355 365 O

Be 0 2 366 368 O
required 3 11 369 377 O
to 12 14 378 380 O
have 15 19 381 385 O
the 20 23 386 389 O
clinical 24 32 390 398 O
diagnosis 33 42 399 408 O
of 43 45 409 411 O
lymphatic 46 55 412 421 B-chronic_disease
malformation 56 68 422 434 I-chronic_disease
that 69 73 435 439 O
appears 74 81 440 447 O
to 82 84 448 450 O
be 85 87 451 453 O
over 88 92 454 458 O
3 93 94 459 460 B-lower_bound
cm 95 97 461 463 I-lower_bound
in 98 100 464 466 I-lower_bound
greatest 101 109 467 475 I-lower_bound
diameter 110 118 476 484 I-lower_bound
in 119 121 485 487 O
order 122 127 488 493 O
to 128 130 494 496 O
be 131 133 497 499 O
evaluated 134 143 500 509 O
for 144 147 510 513 O
entry 148 153 514 519 O

Can 0 3 520 523 O
not 3 6 523 526 O
confirm 7 14 527 534 O
that 15 19 535 539 O
the 20 23 540 543 O
lesion 24 30 544 550 O
is 31 33 551 553 O
a 34 35 554 555 O
lymphatic 36 45 556 565 B-chronic_disease
malformation 46 58 566 578 I-chronic_disease
or 59 61 579 581 O
the 62 65 582 585 O
lymphatic 66 75 586 595 O
malformation 76 88 596 608 O
is 89 91 609 611 O
less 92 96 612 616 O
than 97 101 617 621 O
3 102 103 622 623 B-lower_bound
cm 104 106 624 626 I-lower_bound
in 107 109 627 629 O
its 110 113 630 633 O
greatest 114 122 634 642 O
diameter 123 131 643 651 B-clinical_variable
during 132 138 652 658 O
the 139 142 659 662 O
MRI 143 146 663 666 B-treatment
screening 147 156 667 676 O

Cimetidine 0 10 677 687 B-treatment

Concomitant 0 11 688 699 O
use 12 15 700 703 O
of 16 18 704 706 O
REVATIO 19 26 707 714 B-treatment
with 27 31 715 719 I-treatment
ritonavir 32 41 720 729 I-treatment
and 42 45 730 733 I-treatment
other 46 51 734 739 I-treatment
potent 52 58 740 746 I-treatment
CYP3A 59 64 747 752 I-treatment
inhibitors 65 75 753 763 I-treatment
is 76 78 764 766 O
not 79 82 767 770 O
recommended 83 94 771 782 O

Consistent 0 10 783 793 O
with 11 15 794 798 O
its 16 19 799 802 O
known 20 25 803 808 O
effects 26 33 809 816 O
on 34 36 817 819 O
the 37 40 820 823 O
nitric 41 47 824 830 O
oxide 48 53 831 836 O
/ 53 54 836 837 O
cGMP 54 58 837 841 O
pathway 59 66 842 849 O
, 66 67 849 850 O
sildenafil 68 78 851 861 B-treatment
was 79 82 862 865 O
shown 83 88 866 871 O
to 89 91 872 874 O
potentiate 92 102 875 885 O
the 103 106 886 889 O
hypotensive 107 118 890 901 O
effects 119 126 902 909 O
of 127 129 910 912 O
nitrates 130 138 913 921 B-treatment

Has 0 3 922 925 O
a 4 5 926 927 O
history 6 13 928 935 O
of 14 16 936 938 O
priapism 17 25 939 947 B-chronic_disease
or 26 28 948 950 O
is 29 31 951 953 O
diagnosed 32 41 954 963 O
with 42 46 964 968 O
sickle 47 53 969 975 B-chronic_disease
cell 54 58 976 980 I-chronic_disease
anemia 59 65 981 987 I-chronic_disease
or 66 68 988 990 O
any 69 72 991 994 O
other 73 78 995 1000 O
disorder 79 87 1001 1009 O
which 88 93 1010 1015 O
may 94 97 1016 1019 O
predispose 98 108 1020 1030 O
to 109 111 1031 1033 O
priapism 112 120 1034 1042 O

Has 0 3 1043 1046 O
diagnosis 4 13 1047 1056 O
of 14 16 1057 1059 O
the 17 20 1060 1063 O
soft 21 25 1064 1068 B-cancer
tissue 26 32 1069 1075 I-cancer
tumor 33 38 1076 1081 I-cancer
as 39 41 1082 1084 O
LM 42 44 1085 1087 B-chronic_disease
not 45 48 1088 1091 O
clinically 49 59 1092 1102 O
certain 60 67 1103 1110 O

Has 0 3 1111 1114 O
had 4 7 1115 1118 O
extensive 8 17 1119 1128 O
prior 18 23 1129 1134 B-treatment
surgery 24 31 1135 1142 I-treatment
or 32 34 1143 1145 O
sclerotherapy 35 48 1146 1159 B-treatment
to 49 51 1160 1162 O
treat 52 57 1163 1168 O
LM 58 60 1169 1171 B-chronic_disease
such 61 65 1172 1176 O
that 66 70 1177 1181 O
scarring 71 79 1182 1190 O
may 80 83 1191 1194 O
interfere 84 93 1195 1204 O
with 94 98 1205 1209 O
evaluation 99 109 1210 1220 O
and 110 113 1221 1224 O
treatment 114 123 1225 1234 B-treatment
effect 124 130 1235 1241 O
of 131 133 1242 1244 O
sildenafil 134 144 1245 1255 B-treatment

Has 0 3 1256 1259 O
one 4 7 1260 1263 O
or 8 10 1264 1266 O
more 11 15 1267 1271 O
of 16 18 1272 1274 O
the 19 22 1275 1278 O
following 23 32 1279 1288 O
medical 33 40 1289 1296 B-chronic_disease
conditions 41 51 1297 1307 I-chronic_disease

Has 0 3 1308 1311 O
received 4 12 1312 1320 O
at 13 15 1321 1323 O
least 16 21 1324 1329 O
one 22 25 1330 1333 B-lower_bound
of 26 28 1334 1336 O
the 29 32 1337 1340 O
following 33 42 1341 1350 O
medications 43 54 1351 1362 B-treatment
contraindicated 55 70 1363 1378 O
in 71 73 1379 1381 O
association 74 85 1382 1393 O
with 86 90 1394 1398 O
sildenafil 91 101 1399 1409 B-treatment
within 102 108 1410 1416 O
15 109 111 1417 1419 B-upper_bound
days 112 116 1420 1424 I-upper_bound
of 117 119 1425 1427 O
inclusion 120 129 1428 1437 O

Has 0 3 1438 1441 O
ulcerated 4 13 1442 1451 O
or 14 16 1452 1454 O
currently 17 26 1455 1464 O
infected 27 35 1465 1473 O
LMs 36 39 1474 1477 B-chronic_disease

Have 0 4 1478 1482 O
a 5 6 1483 1484 O
required 7 15 1485 1493 O
MRI 16 19 1494 1497 B-treatment
examination 20 31 1498 1509 O
to 32 34 1510 1512 O
confirm 35 42 1513 1520 O
that 43 47 1521 1525 O
the 48 51 1526 1529 O
lymphatic 52 61 1530 1539 B-cancer
malformation 62 74 1540 1552 I-cancer
is 75 77 1553 1555 O
present 78 85 1556 1563 O
and 86 89 1564 1567 O
is 90 92 1568 1570 O
greater 93 100 1571 1578 O
than 101 105 1579 1583 O
3 106 107 1584 1585 B-lower_bound
cm 108 110 1586 1588 I-lower_bound
in 111 113 1589 1591 O
diameter 114 122 1592 1600 B-clinical_variable
in 123 125 1601 1603 O
order 126 131 1604 1609 O
for 132 135 1610 1613 O
the 136 139 1614 1617 O
subjects 140 148 1618 1626 O
to 149 151 1627 1629 O
receive 152 159 1630 1637 O
medication 160 170 1638 1648 B-treatment
, 170 171 1648 1649 O
which 172 177 1650 1655 O
happens 178 185 1656 1663 O
during 186 192 1664 1670 O
the 193 196 1671 1674 O
initial 197 204 1675 1682 O
screening 205 214 1683 1692 O
evaluation 215 225 1693 1703 O
portion 226 233 1704 1711 O
of 234 236 1712 1714 O
the 237 240 1715 1718 O
trial 241 246 1719 1724 O

Have 0 4 1725 1729 O
had 5 8 1730 1733 O
recurrent 9 18 1734 1743 B-chronic_disease
infection 19 28 1744 1753 I-chronic_disease
and 29 32 1754 1757 O
significant 33 44 1758 1769 O
scarring 45 53 1770 1778 O
of 54 56 1779 1781 O
the 57 60 1782 1785 O
lesion 61 67 1786 1792 O
secondary 68 77 1793 1802 O
to 78 80 1803 1805 O
infection 81 90 1806 1815 O
to 91 93 1816 1818 O
such 94 98 1819 1823 O
an 99 101 1824 1826 O
extent 102 108 1827 1833 O
that 109 113 1834 1838 O
the 114 117 1839 1842 O
that 118 122 1843 1847 O
scarring 123 131 1848 1856 O
may 132 135 1857 1860 O
interfere 136 145 1861 1870 O
with 146 150 1871 1875 O
evaluation 151 161 1876 1886 O
and 162 165 1887 1890 O
treatment 166 175 1891 1900 B-treatment
effect 176 182 1901 1907 O
of 183 185 1908 1910 O
sildenafil 186 196 1911 1921 B-treatment

Have 0 4 1922 1926 O
no 5 7 1927 1929 O
contraindication 8 24 1930 1946 O
to 25 27 1947 1949 O
MRI 28 31 1950 1953 B-treatment
examinations 32 44 1954 1966 O
such 45 49 1967 1971 O
as 50 52 1972 1974 O
metal 53 58 1975 1980 O
implants 59 67 1981 1989 O
, 67 68 1989 1990 O
etc 69 72 1991 1994 O

Have 0 4 1995 1999 O
no 5 7 2000 2002 O
contraindications 8 25 2003 2020 O
for 26 29 2021 2024 O
the 30 33 2025 2028 O
use 34 37 2029 2032 O
of 38 40 2033 2035 O
sildenafil 41 51 2036 2046 B-treatment

Have 0 4 2047 2051 O
the 5 8 2052 2055 O
lymphatic 9 18 2056 2065 B-chronic_disease
malformation 19 31 2066 2078 I-chronic_disease
cause 32 37 2079 2084 O
enough 38 44 2085 2091 O
disability 45 55 2092 2102 O
for 56 59 2103 2106 O
the 60 63 2107 2110 O
subject 64 71 2111 2118 O
that 72 76 2119 2123 O
requires 77 85 2124 2132 O
them 86 90 2133 2137 O
to 91 93 2138 2140 O
consider 94 102 2141 2149 O
systemic 103 111 2150 2158 B-treatment
therapy 112 119 2159 2166 I-treatment

Hepatic 0 7 2167 2174 B-chronic_disease
impairment 8 18 2175 2185 I-chronic_disease
, 18 19 2185 2186 O
severe 20 26 2187 2193 O
renal 27 32 2194 2199 B-chronic_disease
impairment 33 43 2200 2210 I-chronic_disease
, 43 44 2210 2211 O
lymphedema 45 55 2212 2222 B-chronic_disease
conditions 56 66 2223 2233 I-chronic_disease
such 67 71 2234 2238 O
as 72 74 2239 2241 O
Milroy 75 81 2242 2248 B-chronic_disease
disease 82 89 2249 2256 I-chronic_disease
, 89 90 2256 2257 O
Meige 91 96 2258 2263 B-chronic_disease
lymphedema 97 107 2264 2274 I-chronic_disease
, 107 108 2274 2275 O
Hennekam 109 117 2276 2284 B-chronic_disease
syndrome 118 126 2285 2293 I-chronic_disease
, 126 127 2293 2294 O
Njolstad 128 136 2295 2303 B-chronic_disease
syndrome 137 145 2304 2312 I-chronic_disease
, 145 146 2312 2313 O
Aagenaes 147 155 2314 2322 B-chronic_disease
syndrome 156 164 2323 2331 I-chronic_disease
, 164 165 2331 2332 O
and 166 169 2333 2336 O
Fabry 170 175 2337 2342 B-chronic_disease
disease 176 183 2343 2350 I-chronic_disease
, 183 184 2350 2351 O
hypotension 185 196 2352 2363 B-chronic_disease
or 197 199 2364 2366 O
at 200 202 2367 2369 O
risk 203 207 2370 2374 O
for 208 211 2375 2378 O
hypotension 212 223 2379 2390 O
, 223 224 2390 2391 O
seizures 225 233 2392 2400 B-chronic_disease
or 234 236 2401 2403 O
history 237 244 2404 2411 O
of 245 247 2412 2414 O
seizures 248 256 2415 2423 O

Known 0 5 2424 2429 O
to 6 8 2430 2432 O
have 9 13 2433 2437 O
an 14 16 2438 2440 O
allergy 17 24 2441 2448 O
to 25 27 2449 2451 O
sildenafil 28 38 2452 2462 B-allergy_name

Organic 0 7 2463 2470 B-treatment
nitrates 8 16 2471 2479 I-treatment
in 17 19 2480 2482 O
any 20 23 2483 2486 O
form 24 28 2487 2491 O
, 28 29 2491 2492 O
either 30 36 2493 2499 O
regularly 37 46 2500 2509 O
or 47 49 2510 2512 O
intermittently 50 64 2513 2527 O

Participating 0 13 2528 2541 O
in 14 16 2542 2544 O
another 17 24 2545 2552 B-treatment
clinical 25 33 2553 2561 I-treatment
study 34 39 2562 2567 I-treatment
which 40 45 2568 2573 O
may 46 49 2574 2577 O
interfere 50 59 2578 2587 O

Requires 0 8 2588 2596 O
concomitant 9 20 2597 2608 O
use 21 24 2609 2612 O
of 25 27 2613 2615 O
potent 28 34 2616 2622 B-treatment
cytochrome 35 45 2623 2633 I-treatment
P450 46 50 2634 2638 I-treatment
3A4 51 54 2639 2642 I-treatment
inhibitors 55 65 2643 2653 I-treatment
( 66 67 2654 2655 O
such 67 71 2655 2659 O
as 72 74 2660 2662 O
ketoconazole 75 87 2663 2675 B-treatment
, 87 88 2675 2676 O
itraconazole 89 101 2677 2689 B-treatment
, 101 102 2689 2690 O
erythromycin 103 115 2691 2703 B-treatment
, 115 116 2703 2704 O
saquinavir 117 127 2705 2715 B-treatment
) 127 128 2715 2716 O
, 128 129 2716 2717 O
or 130 132 2718 2720 O
concomitant 133 144 2721 2732 O
use 145 148 2733 2736 O
of 149 151 2737 2739 O
ritonavir 152 161 2740 2749 B-treatment

Ritonavir 0 9 2750 2759 B-treatment
and 10 13 2760 2763 O
other 14 19 2764 2769 O
Potent 20 26 2770 2776 B-treatment
CYP3A 27 32 2777 2782 I-treatment
Inhibitors 33 43 2783 2793 I-treatment

any 0 3 2794 2797 O
significant 4 15 2798 2809 O
cardiovascular 16 30 2810 2824 O
risk 31 35 2825 2829 O
factors 36 43 2830 2837 O
and 44 47 2838 2841 O
any 48 51 2842 2845 O
condition 52 61 2846 2855 O
which 62 67 2856 2861 O
requires 68 76 2862 2870 O
participants 77 89 2871 2883 O
to 90 92 2884 2886 O
use 93 96 2887 2890 O
nitric 97 103 2891 2897 O
oxide 104 109 2898 2903 O
donors 110 116 2904 2910 O
or 117 119 2911 2913 O
nitrates 120 128 2914 2922 O
in 129 131 2923 2925 O
any 132 135 2926 2929 O
form 136 140 2930 2934 O
, 140 141 2934 2935 O
underlying 142 152 2936 2946 O
anatomic 153 161 2947 2955 O
or 162 164 2956 2958 O
vascular 165 173 2959 2967 O
risk 174 178 2968 2972 O
factor 179 185 2973 2979 O
for 186 189 2980 2983 O
developing 190 200 2984 2994 O
non 201 204 2995 2998 B-chronic_disease
- 204 205 2998 2999 I-chronic_disease
arteritic 205 214 2999 3008 I-chronic_disease
anterior 215 223 3009 3017 I-chronic_disease
ischemic 224 232 3018 3026 I-chronic_disease
optic 233 238 3027 3032 I-chronic_disease
neuropathy 239 249 3033 3043 I-chronic_disease
( 250 251 3044 3045 I-chronic_disease
NAION 251 256 3045 3050 I-chronic_disease
) 256 257 3050 3051 I-chronic_disease
including 258 267 3052 3061 O
low 268 271 3062 3065 O
ocular 272 278 3066 3072 O
cup 279 282 3073 3076 O
to 283 285 3077 3079 O
disc 286 290 3080 3084 O
ratio 291 296 3085 3090 O
, 296 297 3090 3091 O
diabetes 298 306 3092 3100 B-chronic_disease
, 306 307 3100 3101 O
hypertension 308 320 3102 3114 B-chronic_disease
, 320 321 3114 3115 O
coronary 322 330 3116 3124 B-chronic_disease
artery 331 337 3125 3131 I-chronic_disease
disease 338 345 3132 3139 I-chronic_disease
, 345 346 3139 3140 O
or 347 349 3141 3143 O
hyperlipidemia 350 364 3144 3158 B-chronic_disease
Participants 365 377 3159 3171 O
with 378 382 3172 3176 O
Down 383 387 3177 3181 B-chronic_disease
syndrome 388 396 3182 3190 I-chronic_disease
, 396 397 3190 3191 O
Turner 398 404 3192 3198 B-chronic_disease
syndrome 405 413 3199 3207 I-chronic_disease
and 414 417 3208 3211 O
Noonan 418 424 3212 3218 B-chronic_disease
syndrome 425 433 3219 3227 I-chronic_disease
will 434 438 3228 3232 O
be 439 441 3233 3235 O
considered 442 452 3236 3246 O
on 453 455 3247 3249 O
a 456 457 3250 3251 O
case 458 462 3252 3256 O
- 462 463 3256 3257 O
by 463 465 3257 3259 O
- 465 466 3259 3260 O
case 466 470 3260 3264 O
basis 471 476 3265 3270 O

between 0 7 3271 3278 O
the 8 11 3279 3282 O
ages 12 16 3283 3287 B-age
of 17 19 3288 3290 O
6 20 21 3291 3292 B-lower_bound
months 22 28 3293 3299 I-lower_bound
- 29 30 3300 3301 O
10 31 33 3302 3304 B-upper_bound
years 34 39 3305 3310 I-upper_bound
of 40 42 3311 3313 O
age 43 46 3314 3317 O
at 47 49 3318 3320 O
the 50 53 3321 3324 O
time 54 58 3325 3329 O
of 59 61 3330 3332 O
entry 62 67 3333 3338 O
into 68 72 3339 3343 O
the 73 76 3344 3347 O
study 77 82 3348 3353 O

co 0 2 3354 3356 O
- 2 3 3356 3357 O
administering 3 16 3357 3370 O
alpha 17 22 3371 3376 B-treatment
- 22 23 3376 3377 I-treatment
blockers 23 31 3377 3385 I-treatment
with 32 36 3386 3390 O
REVATIO 37 44 3391 3398 B-treatment
because 45 52 3399 3406 O
of 53 55 3407 3409 O
additive 56 64 3410 3418 O
blood 65 70 3419 3424 O
pressure 71 79 3425 3433 O
- 79 80 3433 3434 O
lowering 80 88 3434 3442 O
effects 89 96 3443 3450 O

female 0 6 3451 3457 B-gender
subjects 7 15 3458 3466 I-gender

must 0 4 3467 3471 O
not 5 8 3472 3475 O
be 9 11 3476 3478 O
pregnant 12 20 3479 3487 B-pregnancy
or 21 23 3488 3490 O
breast 24 30 3491 3497 O
- 30 31 3497 3498 O
feeding 31 38 3498 3505 O

